Open Access<p>Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients</p>
Author(s) -
Achiraya Teyateeti,
Armeen Mahvash,
James P. Long,
Mohamed E. Abdelsalam,
Rony Avritscher,
Beth Chasen,
Ahmed O. Kaseb,
J. Kuban,
Ravi Murthy,
Bruno C. Odisio,
Achiraya Teyateeti,
Homer A. Macapinlac,
S. Cheenu Kappadath
Publication year - 2020
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s248314
Subject(s) - sorafenib , medicine , hepatocellular carcinoma , gastroenterology , progressive disease , adverse effect , oncology , response evaluation criteria in solid tumors , progression free survival , univariate analysis , overall survival , multivariate analysis , disease
To assess the overall survival (OS) and progression-free survival (PFS) of unresectable hepatocellular carcinoma (HCC) patients undergoing yttrium-90 glass-microsphere transarterial radioembolization (TARE) with and without concurrent sorafenib.